Drug Profile

EMP 01

Alternative Names: EMP-01; R-MDMA-HCl

Latest Information Update: 09 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EmpathBio
Class Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists; Serotonin release stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Social phobia
No development reported Post-traumatic stress disorders

Most Recent Events

26 Feb 2026 Efficacy and adverse events data from a phase II trial in Social phobia released by Atai Beckley
12 Feb 2026 AtaiBeckley completes a phase-IIa trial in Social phobia in United Kingdom (PO) (NCT06693609)
11 Dec 2025 Atai Beckley has patent protection for EMP 01 in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com